过去一年中添加的文章,按日期排序

Optimizing the management of inherited blood disorders in a changing market: Findings from the AMCP Market Insights Program

T Richardson, M Rice, R Haumschild, D Hoffer… - Journal of Managed …, 2024 - jmcp.org
10 天前 - … a lifetime estimated cost of $5.4 million per patient. Transfusion-… and cost-effective
use of these novel treatments. … requirement that patients being treated for hemophilia have at …

A descriptive survey of patient experiences and access to specialty medicines with alternative funding programs

WB Wong, I Yermilov, H Dalglish, L Bienvenu, J James… - medRxiv, 2024 - medrxiv.org
12 天前 - change or left their job at a 3–5-fold higher rate than those who reported no impact
from wait time. Patients with hemophilia … pocket cost burden for commercially insured patients

[引用][C] EE318 Reduction of Costs Associated With the Use of Emicizumab in Prophylaxis in Pediatric Patients Diagnosed With Severe Hemophilia A and Inhibitors in El …

A Estrada, C Galdámez, D Castillo… - Value in …, 2024 - valueinhealthjournal.com
41 天前 - … bypass agent versus subsequent change of therapy to emicizumab. … patient the
annual care costs were reduced by 56.21% and in the second patient the six-monthly care costs

EE706 Impact of Valoctocogene Roxaparvovec on the Economic Burden of Adults with Severe Hemophilia A Managed with Prophylaxis in the United States

T Wang, E Chen, C Regan, K Cook… - Value in …, 2023 - valueinhealthjournal.com
224 天前 - … healthcare resource utilisation and costs for newly diagnosed FXS patients. Methods:
… to estimate the change in burden of a cohort of adult males with severe hemophilia A …

… Systemic Bevacizumab Therapy Produces Cost Savings and Improves Quality-Adjusted Life Expectancy in the Care of Patients with Hereditary Hemorrhagic …

D Wang, S Ito, C Waldron, A Butt, E Zhang… - Blood, 2023 - Elsevier
227 天前 - … Unlike peer disorders hemophilia and von Willebrand … that no parameter variance
changes the model result. In … : saving cost with increased QALYs in 99.6% and cost-effective …

A Single Center Experience of 13 Episodes of Acquired Hemophilia A (2019-2023)

E Paredes, KE Dane, J Lindsley, RPP Naik, M Streiff… - Blood, 2023 - Elsevier
227 天前 - … aPCC was the rst-line BPA administered in all patients, with signi cant cost savings
relative to rFVIIa. Immunosuppres- sion, including prednisone and either cyclophosphamide …

Keeping up with the Cartashians-Classical Hematology Drug Approvals over Past 5 Years

S Shah, L Padrnos, RK Pruthi, RS Go - Blood, 2023 - Elsevier
227 天前 - … This is changing how we treat patients with classical … Lastly, management of
hemophilia is being revolutionized … Hemophilia care has always been deemed to be costly, …

Economic and Clinical Impact Evaluation of AI-Aided Point-of-Care Ultrasound (POCUS) in the Management of Early-Stage Joint Damage in Hemophilia

A Nagao, K Kido, Y Nakamoto, Y Yoshida, K Fukutake - Blood, 2023 - Elsevier
227 天前 - … in hemophilia patients. Most modifications involved increasing doses, shortening
intervals, and changing … assumes the ‘additional cost is uniformly fixed for all patients’, which …

Advancing Hemophilia Prophylaxis: Personalized Low-Dose CFC and Emicizumab in Resource-Limited Settings

S Francis, VN Pillai, TM Sajithamony, SG Chiramal… - Blood, 2023 - Elsevier
227 天前 - Patients were regularly followed up in the Hemophilia … Prophylaxis outcomes
were assessed with changes in ABR … the patient characteristics, prophylaxis dose, cost and …

Reducing Preventable Bleeding Visits and Institutional Factor Costs for Patients with Bleeding Disorders with a Prospective Quality Improvement Project

S Merrill, S Webber, L Merrill, M Varvoutis… - Blood, 2023 - Elsevier
227 天前 - … that could have been potentially prevented by changes in outpatient care delivery.
cost, use of prophylaxis in severe hemophilia, primary care physician attainment, and patient